| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.M110.111559 |
| P8608 | Fatcat ID | release_lqjblkujfbddna2j2fibwshf6m |
| P932 | PMC publication ID | 2903410 |
| P698 | PubMed publication ID | 20463019 |
| P50 | author | Johannes-Peter Stasch | Q66360867 |
| Annie Beuve | Q110334025 | ||
| Focco van den Akker | Q28320730 | ||
| P2093 | author name string | Faye Martin | |
| Focco van den Akker | |||
| Martina Schaefer | |||
| Padmamalini Baskaran | |||
| Pete W Dunten | |||
| Xiaolei Ma | |||
| P2860 | cites work | Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases | Q37511692 |
| Expression and characterization of the catalytic domains of soluble guanylate cyclase: interaction with the heme domain | Q39369792 | ||
| Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation | Q39845753 | ||
| Functional characterization of nitric oxide and YC-1 activation of soluble guanylyl cyclase: structural implication for the YC-1 binding site? | Q42458596 | ||
| Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase | Q44626758 | ||
| Femtomolar sensitivity of a NO sensor from Clostridium botulinum. | Q45096466 | ||
| Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase | Q46476857 | ||
| PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. | Q48785859 | ||
| Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide | Q70930193 | ||
| Identification of residues crucially involved in soluble guanylate cyclase activation | Q79871327 | ||
| NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential | Q24656131 | ||
| PROCHECK: a program to check the stereochemical quality of protein structures | Q26778411 | ||
| Processing of X-ray diffraction data collected in oscillation mode | Q26778468 | ||
| NO and CO differentially activate soluble guanylyl cyclase via a heme pivot-bend mechanism | Q27641107 | ||
| A structural basis for H-NOX signaling in Shewanella oneidensis by trapping a histidine kinase inhibitory conformation | Q27658207 | ||
| Coot: model-building tools for molecular graphics | Q27860505 | ||
| Macromolecular TLS refinement in REFMAC at moderate resolutions | Q27860526 | ||
| Heme is involved in microRNA processing | Q28278198 | ||
| Detecting and overcoming crystal twinning | Q29620960 | ||
| Objective comparison of protein structures: error-scaled difference distance matrices | Q33922462 | ||
| NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle | Q35044464 | ||
| Drugs that activate specific nitric oxide sensitive guanylyl cyclase isoforms independent of nitric oxide release | Q35060954 | ||
| Heme-based sensors: defining characteristics, recent developments, and regulatory hypotheses | Q35983689 | ||
| Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development | Q36648534 | ||
| The role of transporters in cellular heme and porphyrin homeostasis | Q36763207 | ||
| Modulation of cGMP in heart failure: a new therapeutic paradigm | Q37329891 | ||
| NO- and haem-independent soluble guanylate cyclase activators | Q37352787 | ||
| Discovery of the nitric oxide signaling pathway and targets for drug development | Q37409901 | ||
| P433 | issue | 29 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| nitrogen oxide | Q424418 | ||
| P1104 | number of pages | 7 | |
| P304 | page(s) | 22651-22657 | |
| P577 | publication date | 2010-05-12 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase | |
| P478 | volume | 285 |
| Q35743176 | A new small molecule inhibitor of soluble guanylate cyclase |
| Q64069313 | A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation |
| Q41329824 | Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway |
| Q46556756 | Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice. |
| Q42863913 | Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase |
| Q39200522 | Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention. |
| Q35855521 | Aspartate 102 in the heme domain of soluble guanylyl cyclase has a key role in NO activation |
| Q39320532 | Bacterial Haemoprotein Sensors of NO: H-NOX and NosP. |
| Q57628743 | Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes |
| Q35776824 | Cobinamides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain |
| Q58696712 | Comparative Studies of the Dynamics Effects of BAY60-2770 and BAY58-2667 Binding with Human and Bacterial H-NOX Domains |
| Q24336722 | Crystal structures of the catalytic domain of human soluble guanylate cyclase |
| Q43862233 | Dynamic change of heme environment in soluble guanylate cyclase and complexation of NO-independent drug agents with H-NOX domain |
| Q27021649 | Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS |
| Q28741339 | Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells |
| Q42600835 | Gaseotransmitters: new frontiers for translational science |
| Q30539237 | Higher-order interactions bridge the nitric oxide receptor and catalytic domains of soluble guanylate cyclase. |
| Q28477878 | Identification of residues in the heme domain of soluble guanylyl cyclase that are important for basal and stimulated catalytic activity |
| Q55333337 | Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form. |
| Q41770411 | Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat |
| Q27677544 | Insights into BAY 60-2770 Activation and S -Nitrosylation-Dependent Desensitization of Soluble Guanylyl Cyclase via Crystal Structures of Homologous Nostoc H-NOX Domain Complexes |
| Q27680135 | Insights into Soluble Guanylyl Cyclase Activation Derived from Improved Heme-Mimetics |
| Q36713981 | Molecular model of a soluble guanylyl cyclase fragment determined by small-angle X-ray scattering and chemical cross-linking |
| Q41848414 | Nitric oxide activation of guanylate cyclase pushes the α1 signaling helix and the β1 heme-binding domain closer to the substrate-binding site. |
| Q34075870 | Nitric oxide and heat shock protein 90 activate soluble guanylate cyclase by driving rapid change in its subunit interactions and heme content. |
| Q37727207 | Nitric oxide-induced conformational changes in soluble guanylate cyclase |
| Q37887771 | Nitric oxide: a guardian for vascular grafts? |
| Q39038560 | Nitric oxide: what's new to NO? |
| Q35083181 | Oxidation and loss of heme in soluble guanylyl cyclase from Manduca sexta |
| Q88500342 | Physiological activation and deactivation of soluble guanylate cyclase |
| Q30251531 | Potential new drug treatments for congestive heart failure |
| Q37476512 | Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice |
| Q37660997 | Probing the Molecular Mechanism of Human Soluble Guanylate Cyclase Activation by NO in vitro and in vivo |
| Q41971888 | Quaternary structure controls ligand dynamics in soluble guanylate cyclase |
| Q38777323 | Regulation of sGC via hsp90, Cellular Heme, sGC Agonists, and NO: New Pathways and Clinical Perspectives |
| Q37697630 | Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow. |
| Q87418632 | Small alterations in cobinamide structure considerably influence sGC activation |
| Q35010064 | Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease |
| Q38012596 | Soluble guanylate cyclase: a potential therapeutic target for heart failure |
| Q36167665 | Soluble guanylyl cyclase requires heat shock protein 90 for heme insertion during maturation of the NO-active enzyme |
| Q47603923 | Stimulators and activators of soluble guanylate cyclase for urogenital disorders |
| Q38894826 | Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor |
| Q55436230 | Structure/function of the soluble guanylyl cyclase catalytic domain. |
| Q38180766 | Structures of soluble guanylate cyclase: implications for regulatory mechanisms and drug development |
| Q38646890 | Surface plasmon resonance using the catalytic domain of soluble guanylate cyclase allows the detection of enzyme activators |
| Q64939078 | The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective. |
| Q38130465 | The chemistry and biology of soluble guanylate cyclase stimulators and activators |
| Q34042836 | The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies |
| Q54185546 | Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm. |
| Q37980659 | cGMP becomes a drug target |
Search more.